90-day fills for chronic hepatitis B treatments increased patient adherence

Being prescribed a 90-day or a “mixed duration” supply of entecavir or tenofovir disoproxil fumarate was associated with higher fill rates among commercially insured patients with chronic hepatitis B, researchers found.“There has been a lot of important research on barriers that prevent patients with chronic hepatitis B (CHB) from receiving the care they need,” Jonathan…

VIDEO: Healio Lifetime Disruptor winner highlights need to ‘eliminate disparities’ in GI

In a Healio video exclusive, Mark B. Pochapin, MD, winner of the 2022 Healio Lifetime Disruptor Award, shares his perspective about advances in gastroenterology over the past few decades and how the field will progress in years to come.“I am really thrilled because it allows me to reflect on what was disruptive technology or innovation…